Structure Therapeutics Inc.
GPCR
$19.61
$0.241.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.74M | 13.44M | 13.57M | 13.24M | 11.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.45M | 56.31M | 47.06M | 45.84M | 33.32M |
| Operating Income | -70.45M | -56.31M | -47.06M | -45.84M | -33.32M |
| Income Before Tax | -61.52M | -46.74M | -36.34M | -33.89M | -25.98M |
| Income Tax Expenses | 139.00K | 98.00K | 136.00K | 92.00K | 53.00K |
| Earnings from Continuing Operations | -61.66M | -46.83M | -36.48M | -33.98M | -26.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.66M | -46.83M | -36.48M | -33.98M | -26.03M |
| EBIT | -70.45M | -56.31M | -47.06M | -45.84M | -33.32M |
| EBITDA | -70.16M | -56.04M | -46.80M | -45.56M | -33.08M |
| EPS Basic | -3.21 | -2.45 | -1.91 | -1.78 | -1.58 |
| Normalized Basic EPS | -0.67 | -0.51 | -0.26 | -0.37 | -0.33 |
| EPS Diluted | -3.21 | -2.45 | -1.91 | -1.78 | -1.58 |
| Normalized Diluted EPS | -0.67 | -0.51 | -0.26 | -0.37 | -0.33 |
| Average Basic Shares Outstanding | 57.55M | 57.35M | 57.30M | 57.21M | 49.41M |
| Average Diluted Shares Outstanding | 19.18M | 19.12M | 19.10M | 19.07M | 16.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |